Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
3.400
-0.155 (-4.36%)
At close: Aug 28, 2026, 4:00 PM EDT
3.410
+0.010 (0.29%)
After-hours: Aug 28, 2026, 4:04 PM EDT
Cellectis Employees
As of December 31, 2025, Cellectis had 229 total employees, including 224 full-time and 5 part-time employees. The number of employees increased by 7 or 3.15% compared to the previous year.
Employees
229
Change (1Y)
7
Growth (1Y)
3.15%
Revenue / Employee
$278,703
Profits / Employee
-$285,214
Market Cap
256.64M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 229 | 7 | 3.15% | 224 | 5 |
| Dec 31, 2024 | 222 | 1 | 0.45% | 216 | 6 |
| Dec 31, 2023 | 221 | -16 | -6.75% | 216 | 5 |
| Dec 31, 2022 | 237 | -63 | -21.00% | 231 | 6 |
| Dec 31, 2021 | 300 | 19 | 6.76% | 294 | 6 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Entrada Therapeutics | 152 |
| AC Immune | 122 |
| Niagen Bioscience | 117 |
| Alector | 103 |
| Neumora Therapeutics | 63 |
| Sionna Therapeutics | 59 |
| Camp4 Therapeutics | 48 |
CLLS News
- 24 days ago - Cellectis reports Q2 adjusted EPS (35c) vs (40c) last year - TheFly
- 24 days ago - Cellectis Reports Financial Results for the Second Quarter 2026 - GlobeNewsWire
- 24 days ago - Cellectis Earnings release: H1 2026 - Filings
- 25 days ago - Monthly information on share capital and company voting rights - GlobeNewsWire
- 4 weeks ago - Cellectis to Report Second Quarter Financial Results on August 6, 2026 - GlobeNewsWire
- 6 weeks ago - Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio - GlobeNewsWire
- 2 months ago - Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 - GlobeNewsWire
- 2 months ago - Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress - GlobeNewsWire